Browse our 650+ Publications​

Jennifer A White 1, Fengting Wu 1, Saif Yasin 2, Milica Moskovljevic 1, Joseph Varriale 1, Filippo Dragoni 1, Angelica Camilo-Contreras 1, Jiayi Duan 1, Mei Y Zheng 2, Ndeh F Tadzong 2, Heer B Patel 2, Jeanelle Mae C Quiambao 2, Kyle Rhodehouse 1, Hao Zhang 3, Jun Lai 1, Subul A Beg 1, Michael Delannoy 4, Christin Kilcrease 1, Christopher J Hoffmann 1, Sébastien Poulin 5, Frédéric Chano 5, Cécile Tremblay 6,7, Jerald Cherian 1, Patricia Barditch-Crovo 1, Natasha Chida 1, Richard D Moore 1, Michael F Summers 2,8, Robert F Siliciano 1,8, Janet D Siliciano 1, Francesco R Simonetti 1; 1 Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 2 Department of Chemistry and Biochemistry, University of Maryland, Baltimore County, Baltimore, Maryland, USA. 3 Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. 4 Institute for Basic Biomedical Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. 5 Clinique L’Agora, Montreal, Canada. 6 Centre de Recherche du Centre Hospitalier de l’Université de Montréal (CHUM), Montreal, Canada. 7 Département de Microbiologie, Immunologie et Infectiologie, Université de Montréal, Montreal, Canada. 8 Howard Hughes Medical Institute, Baltimore, Maryland, USA.

Rachel Thomas 1, Jiyoung Oh 2, Weikan Wang 1, Dong-Ming Su 3; 1 Graduate School of Biomedical Sciences, University of North Texas Health Science Center, Fort Worth, TX, USA. 2 Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3 Department of Microbiology, Immunology and Genetics, University of North Texas Health Science Center, Fort Worth, TX, USA.

Meenal Sinha 1, Courtney Betts 2, Li Zhang 1,3, Madeline J Griffith 1, Isabelle Solman 4, Brandon Chen 1, Eric Liu 1, Whitney Tamaki 1, Jacob Stultz 1, Jaqueline Marquez 1, Shamilene Sivagnanam 2, Alexander Cheung 1, Denise Pener 5, Anne Fahlman 5, Erin Taber 5, Kimberly Lerner 5, Matthew Crocker 5, Kendra Todd 5, Brindha Rajagopalan 5, Clarisha Ware 1, Mark Bridge 1, Johnson Vo 5, Hannah Dragomanovich 1, Julie Sudduth-Klinger 1, Gina Vaccaro 6, Charles D Lopez 2,5, Margaret Tempero 1, Lisa M Coussens # 2, Lawrence Fong # 7,8; 1 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA. 2 Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA. 3 Department of Biostatistics, University of California, San Francisco, California, USA. 4 AbbVie, Irvine, California, USA. 5 Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA. 6 Medical Oncology, Providence Portland Medical Center, Portland, Oregon, USA. 7 Division of Hematology/Oncology, Department of Medicine, University of California, San Francisco, California, USA lawrence.fong@ucsf.edu. 8 Parker Institute for Cancer Immunotherapy, San Francisco, California, USA. #Contributed equally.

Tara K Sigdel 1, Paul A Fields 2, Juliane Liberto 1, Izabella Damm 1, Maggie Kerwin 1, Jill Hood 2, Parhom Towfighi 1, Marina Sirota 1, Harlan S Robins 2, Minnie M Sarwal 1; 1 Department of Surgery, Division of Multi Organ Transplantation, University of California, San Francisco, San Francisco, CA, United States. 2 Adaptive Biotechnologies, Seattle, WA, United States.

Many acute myeloid leukemia (AML) patients exhibit hallmarks of immune exhaustion, such as increased myeloid-derived suppressor cells, suppressive regulatory T cells and dysfunctional T cells. Similarly, we have identified the same immune-related features, including exhausted CD8+ T cells (TEx) in a mouse model of AML. Here we show that inhibitors that target bromodomain and extra-terminal domain (BET) proteins affect tumor-intrinsic factors but also rescue T cell exhaustion and ICB resistance. Ex vivo treatment of cells from AML mice and AML patients with BET inhibitors (BETi) reversed CD8+ T cell exhaustion by restoring proliferative capacity and expansion of the more functional precursor-exhausted T cells. This reversal was enhanced by combined BETi and anti-PD1 treatment. BETi synergized with anti-PD1 in vivo, resulting in the reduction of circulating leukemia cells, enrichment of CD8+ T cells in the bone marrow, and increase in expression of Tcf7, Slamf6, and Cxcr5 in CD8+ T cells. Finally, we profiled the epigenomes of in vivo JQ1-treated AML-derived CD8+ T cells by single-cell ATAC-seq and found that JQ1 increases Tcf7 accessibility specifically in Tex cells, suggesting that BETi likely acts mechanistically by relieving repression of progenitor programs in Tex CD8+ T cells and maintaining a pool of anti-PD1 responsive CD8+ T cells.

Jara Palomero 1, Carla Panisello 1, Maria Lozano-Rabella 1, Ricky Tirtakasuma 1, Judit Díaz-Gómez 1, Daniela Grases 1, Helena Pasamar 1, Laura Arregui 2, Eduard Dorca Duch 3, Esther Guerra Fernández 3, Ana Vivancos 4, Carlos E de Andrea 5,6, Ignacio Melero 6,7,8, Jordi Ponce 9, August Vidal 3,6, Josep Maria Piulats 10, Xavier Matias-Guiu 3,6,11, Alena Gros 12; 1 Tumor Immunology and Immunotherapy, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain. 2 HUB-ICO-IDIBELL Biobank, Bellvitge Institute for Biomedical Research, L’Hospitalet de Llobregat, Spain. 3 Pathology, Bellvitge University Hospital, IDIBELL, L’Hospitalet de Llobregat, Spain. 4 Cancer Genomics, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain. 5 Pathology, Clinica Universidad de Navarra, Pamplona, Spain. 6 Centro de Investigación Biomedica en Red de Cáncer (CIBERONC), Madrid, Spain. 7 Program of Immunology and Immunotherapy, CIMA Universidad de Navarra, Pamplona, Spain. 8 Navarra Institute for Health Research IDISNA, Pamplona, Spain. 9 Department of Gynaecology, Bellvitge University Hospital, L’Hospitalet de Llobregat, Spain. 10 Medical Oncology, Catalan Institute of Oncology (ICO), IDIBELL-OncoBell, L’Hospitalet de Llobregat, Spain. 11 Pathology, Arnau de Vilanova University Hospital, University of LLeida, IRBLLEIDA, Lleida, Spain. 12 Tumor Immunology and Immunotherapy, Vall d’Hebron Institute of Oncology (VHIO), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain agros@vhio.net.

María Ruiz Ortega 1, Natanael Spisak 1, Thierry Mora 1, Aleksandra M Walczak 1; 1 Laboratoire de physique de l’École Normale Supérieure, CNRS, PSL University, Sorbonne Université, and Université de Paris, Paris, France.

Munyaradzi Musvosvi #1, Huang Huang #2, Chunlin Wang 2, Qiong Xia 2, Virginie Rozot 1, Akshaya Krishnan 3, Peter Acs 3, Abhilasha Cheruku 3, Gerlinde Obermoser 3, Alasdair Leslie 4,5,6, Samuel M Behar 7, Willem A Hanekom 1,4,5, Nicole Bilek 1, Michelle Fisher 1, Stefan H E Kaufmann 8,9,10, Gerhard Walzl 11, Mark Hatherill 1, Mark M Davis #2,12,13, Thomas J Scriba #14; 1 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. 2 Institute for Immunity, Transplantation and Infection, Stanford University School of Medicine, Stanford, CA, USA. 3 Human Immune Monitoring Center, Stanford University, Stanford, CA, USA. 4 Africa Health Research Institute, Durban, South Africa. 5 School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban, South Africa. 6 Department of Infection and Immunity, University College London, London, UK. 7 Department of Microbiology and Physiological Systems, University of Massachusetts Chan Medical School, Worcester, MA, USA. 8 Max Planck Institute for Infection Biology, Berlin, Germany. 9 Max Planck Institute for Multidisciplinary Sciences, Göttingen, Germany. 10 Hagler Institute for Advanced Study, Texas A&M University, College Station, TX, USA. 11 DST-NRF Centre of Excellence for Biomedical Tuberculosis Research, South African Medical Research Council Centre for Tuberculosis Research; Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa. 12 Howard Hughes Medical Institute, Stanford University, Stanford, CA, USA. 13 Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, CA, USA. 14 South African Tuberculosis Vaccine Initiative, Institute of Infectious Disease and Molecular Medicine, and Division of Immunology, Department of Pathology, University of Cape Town, Cape Town, South Africa. thomas.scriba@uct.ac.za. #Contributed equally.

Melissa C Leeolou, Peter A Young, Atif Saleem, Saisindhu Narala, Gordon H Bae 1; 1 Department of Dermatology, Stanford University School of Medicine, Stanford, California, USA

Jani Huuhtanen 1,2,3,4, Henna Kasanen 1,2,4, Katriina Peltola 4,5, Tapio Lönnberg 6, Virpi Glumoff 7, Oscar Brück 1,2,4, Olli Dufva 1,2,4, Karita Peltonen 1,2,4, Johanna Vikkula 3, Emmi Jokinen 1,2,3,4, Mette Ilander 1,2, Moon Hee Lee 1,2,4, Siru Mäkelä 5, Marta Nyakas 8, Bin Li 9, Micaela Hernberg 5, Petri Bono 5, Harri Lähdesmäki 3, Anna Kreutzman 1,2, Satu Mustjoki 1,2,4; 1 Translational Immunology Research Program and Department of Clinical Chemistry and Hematology, University of Helsinki, Helsinki, Finland. 2 Hematology Research Unit Helsinki, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 3 Department of Computer Science, Aalto University, Espoo, Finland. 4 iCAN Digital Precision Cancer Medicine Flagship, Helsinki, Finland. 5 Department of Oncology, Helsinki University Hospital Comprehensive Cancer Center, Helsinki, Finland. 6 Turku Bioscience Centre, University of Turku and Åbo Akademi University, Turku, Finland. 7 Research Unit of Biomedicine, Medical Microbiology and Immunology, University of Oulu, Oulu, Finland. 8 Oslo University Hospital-Radiumhospitalet, Oslo, Norway. 9 Bristol Myers Squibb (BMS) Research and Development, Princeton, New Jersey, USA.